Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Treasury Shares (2019 - 2025)

Historic Treasury Shares for Nurix Therapeutics (NRIX) over the last 7 years, with Q4 2025 value amounting to $2.2 million.

  • Nurix Therapeutics' Treasury Shares rose 1481.7% to $2.2 million in Q4 2025 from the same period last year, while for Nov 2025 it was $2.2 million, marking a year-over-year increase of 1481.7%. This contributed to the annual value of $2.2 million for FY2025, which is 1481.7% up from last year.
  • According to the latest figures from Q4 2025, Nurix Therapeutics' Treasury Shares is $2.2 million, which was up 1481.7% from $2.7 million recorded in Q3 2025.
  • Nurix Therapeutics' 5-year Treasury Shares high stood at $3.0 million for Q1 2025, and its period low was $971.0 during Q1 2021.
  • Its 5-year average for Treasury Shares is $1.4 million, with a median of $1.5 million in 2023.
  • Its Treasury Shares has fluctuated over the past 5 years, first crashed by 9990.29% in 2024, then skyrocketed by 19538191.21% in 2025.
  • Over the past 5 years, Nurix Therapeutics' Treasury Shares (Quarter) stood at $20000.0 in 2021, then surged by 3824.12% to $784824.0 in 2022, then soared by 58.77% to $1.2 million in 2023, then skyrocketed by 56.98% to $2.0 million in 2024, then grew by 14.82% to $2.2 million in 2025.
  • Its Treasury Shares stands at $2.2 million for Q4 2025, versus $2.7 million for Q3 2025 and $3.0 million for Q2 2025.